Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01096979 · ClinicalTrials.gov registry record · Phase 2

An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity

A Phase 2 study, sponsored by Neothetics.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT01096979 is a Phase 2 study that has completed, run by Neothetics. The registered enrollment target is 60 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01096979, a Phase 2 study, has completed, sponsored by Neothetics.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.

Interventions

  • DRUG Placebo
  • DRUG LIPO-102

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2009-10
Est. Completion 2010-03
Phase Phase 2

Sponsor

Neothetics

9 total trials

What the Registry Record Tells You About NCT01096979

The ClinicalTrials.gov registry entry for NCT01096979 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neothetics, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01096979 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01096979 about?

NCT01096979 is a clinical study titled "An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity". This is a double-masked evaluation of the safety and efficacy of LIPO-102 for the reduction of subcutaneous abdominal adiposity.

What is the current status of trial NCT01096979?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2009-10. Estimated completion is 2010-03.

What interventions are being tested in trial NCT01096979?

The interventions under investigation include: Placebo (DRUG), LIPO-102 (DRUG).

Who is sponsoring clinical trial NCT01096979?

This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.